Biomanufacturing & Fermentation Technology

prasad ernala

Welcome to Biomanufacturing & Fermentation Technology, the podcast where microbes meet manufacturing and science turns into scalable reality. In each episode, we dive inside real bioprocesses. from lab-scale experiments to commercial fermenters. to unpack how products are actually made, fixed, and optimized in the real world. Expect candid conversations on fermentation failures and breakthroughs, scale-up war stories, regulatory realities, emerging technologies, and the decisions that separate a promising culture from a profitable process. Whether you are a scientist, engineer, entrepreneur, o

  1. Downstream Digital Twins: Predicting Performance and Managing Process Drift

    -15 H

    Downstream Digital Twins: Predicting Performance and Managing Process Drift

    Downstream bioprocessing is often unstable due to upstream variability and equipment aging. Digital twins use mechanistic and hybrid models to predict fouling, optimize chromatography, and perform root-cause analysis, shifting DSP from reactive craft to predictive science. Downstream Digital Twins Are Shifting DSP From Reactive Firefighting to Predictive Control Mechanistic and hybrid digital twins across clarification, chromatography, and UF/DF are enabling earlier detection of fouling, breakthrough drift, and endpoint risk, before yield and schedule are lost. DSP Failures Are Rarely Single-Point Issues. Variability Chains Start Upstream and Surface Downstream Industry evidence reinforces that harvest properties such as viscosity, conductivity, solids, and impurity maps act as boundary conditions that dominate DSP performance, challenging siloed optimization models. Hybrid and Surrogate Models Are Making Mechanistic Chromatography Usable in Real Time Accelerated solvers built on mechanistic foundations are emerging as practical tools for in-run optimization and hypothesis testing, though governance gaps remain a major adoption risk. Root-Cause Analysis Is Becoming a Primary Value Driver for DSP Digital Twins Instead of post-hoc opinions, digital twins are increasingly used to test resin aging, buffer deviation, feed variability, and equipment drift in silico, supporting continued process verification and deviation investigations. Organizational Incentives, Not Technology, Are the Biggest Barrier to Co-Twin Success Without shared upstream–downstream KPIs and robust event capture, digital twins risk becoming sophisticated blame-assignment tools rather than systems that prevent variability and yield loss. #Bioprocess #ScaleUp and #TechTransfer,#Industrial #Microbiology,#MetabolicEngineering and #SystemsBiology,#Bioprocessing,#MicrobialFermentation,#Bio-manufacturing,#Industrial #Biotechnology,#Fermentation Engineering,#ProcessDevelopment,#Microbiology,#Biochemistry,#Biochemical Engineering, #Applied #MicrobialPhysiology, #Microbial #ProcessEngineering, #Upstream #BioprocessDevelopment, #Downstream Processing and #Purification,#CellCulture and #MicrobialSystems Engineering, #Bioreaction #Enzymes, #Biocatalyst #scientific #Scientist #Research

    15 min
  2. Microbe-Derived Therapeutics: Next-Generation Drug Discovery Through Engineered Microbial Systems

    -1 J

    Microbe-Derived Therapeutics: Next-Generation Drug Discovery Through Engineered Microbial Systems

    The emergence of microbe-derived therapeutics represents a fundamental shift from traditional drug discovery toward the use of engineered biological systems as both production factories and living medicines. These sources explain how advancements in synthetic biology and genetic engineering allow microbes to synthesize complex molecules, such as insulin, or act as intelligent couriers that sense and treat disease locally within the body. Unlike static chemical drugs, these living agents must be designed for evolutionary stability and biocontainment to ensure they do not mutate or persist unintentionally. The literature emphasizes that while AI and CRISPR accelerate the design of these systems, success depends on managing the metabolic burden placed on the host cell and navigating unique regulatory and safety hurdles. Ultimately, the field is moving toward a model where functional complexity is encoded directly into genetic programs, offering new solutions for targets that are unreachable by conventional small molecules. #Bioprocess #ScaleUp and #TechTransfer,#Industrial #Microbiology,#MetabolicEngineering and #SystemsBiology,#Bioprocessing,#MicrobialFermentation,#Bio-manufacturing,#Industrial #Biotechnology,#Fermentation Engineering,#ProcessDevelopment,#Microbiology,#Biochemistry,#Biochemical Engineering, #Applied #MicrobialPhysiology, #Microbial #ProcessEngineering, #Upstream #BioprocessDevelopment, #Downstream Processing and #Purification,#CellCulture and #MicrobialSystems Engineering, #Bioreaction #Enzymes, #Biocatalyst #scientific #Scientist #Research

    17 min
  3. Bio-manufacturing and Fermentation Technology. (2026 February first week edition)

    -2 J

    Bio-manufacturing and Fermentation Technology. (2026 February first week edition)

    Across microbial fermentation and bio-catalysis, new data is forcing us to rethink where cost curves bend, where scale-up really fails, and where regulation is no longer the bottleneck we thought it was. If you are designing strains, scaling reactors, running manufacturing campaigns, or deciding where to place your next technical bet, this week’s signals matter. Upstream: B. licheniformis OP16‑2 converts untreated corn steep water to lactic acid under thermo‑alkaline conditions without nutrient supplementation, challenging the “must‑sterilize + must‑supplement” assumption. Scale reality: At industrial volume, spatial gradients and high shear can collapse uptake/viability and cascade into DSP fouling—robust operating points often beat “optimal” lab settings. Infrastructure signal: BioMADE is building shared pilot capacity (up to 10,000‑L fermenters plus downstream) to de‑risk scale-up for many teams without each one funding full CAPEX. Contrarian (boardroom): “Cell‑free scales universally” is constrained by mass‑balance/energy economics at larger volumes, so it tends to fit niche high‑value use cases or hybrid workflows rather than bulk commodities. Governance: FDA’s Jan 2025 draft guidance formalizes a risk‑based credibility framework for using AI model outputs in regulatory decision‑making for drugs/biologics, making data/validation strategy a competitive lever. References: 1.       Selim,M.T., Salem, S.S., El-Belely, E.F. et al. Nutrient-free biorefinery of corn steepwater into lactic acid by Bacillus licheniformis OP16-2 under thermo-alkaline conditions witha pilot-scale assessment. Sci Rep 16, 4357 (2026).https://doi.org/10.1038/s41598-026-35828-4 ​#Bioprocess #ScaleUp and #TechTransfer,#Industrial #Microbiology,#MetabolicEngineering and #SystemsBiology,#Bioprocessing,#MicrobialFermentation,#Bio-manufacturing,#Industrial #Biotechnology,#Fermentation Engineering,#ProcessDevelopment,#Microbiology,#Biochemistry,#Biochemical Engineering, #Applied #MicrobialPhysiology, #Microbial #ProcessEngineering, #Upstream #BioprocessDevelopment, #Downstream Processing and #Purification,#CellCulture and #MicrobialSystems Engineering, #Bioreaction #Enzymes, #Biocatalyst #scientific #Scientist #Research

    11 min
  4. Risk Allocation in Industrial Microbial Biomass Separation

    -3 J

    Risk Allocation in Industrial Microbial Biomass Separation

    The primary focus of this episode is to explore a framework for managing biomass separation in industrial microbial manufacturing, framing it as a strategic exercise in risk allocation rather than simple efficiency maximization. It evaluates the physical and economic trade-offs between centrifugation, which carries risks related to mechanical shear and impurity propagation, and filtration, which is bounded by fouling kinetics and consumable costs. The discussion emphasize that industrial robustness is determined by coupled variables like particle population dynamics and hydrodynamics, where failures often manifest as reduced downstream capacity or increased downtime. To mitigate these risks, the text advocates for hybrid separation trains that distribute the burden of clarifying complex broths across multiple stages to ensure process stability. Ultimately, the documentation suggests using predictive monitoring, such as tracking pressure rise rates and turbidity slopes, to maintain predictable performance across large-scale production campaigns. #Bioprocess #ScaleUp and #TechTransfer, #Industrial #Microbiology, #MetabolicEngineering and #SystemsBiology, #Bioprocessing, #MicrobialFermentation, #Bio-manufacturing, #Industrial #Biotechnology, #Fermentation Engineering, #ProcessDevelopment, #Microbiology, #Biochemistry #Biochemical Engineering, #Applied #MicrobialPhysiology, #Microbial #ProcessEngineering, #Upstream #BioprocessDevelopment, #Downstream Processing and #Purification, #CellCulture and #MicrobialSystems Engineering, #Bioreaction #Enzymes #Biocatalyst #scientific #Scientist #Research

    19 min
  5. Quantum Fermentation: Exploring Sub-Atomic Interactions for Enhanced Yield

    -4 J

    Quantum Fermentation: Exploring Sub-Atomic Interactions for Enhanced Yield

    The most credible “quantum lever” in fermentation is not macroscopic entanglement across cells; it is the possibility that some rate‑limiting metabolic steps already rely partly on quantum tunneling of hydrogen, and that enzymes modulate tunneling through protein dynamics and active-site geometry. This implies a nontrivial proposition: for specific steps, improving yield may require engineering not only binding and classical transition-state stabilization, but also the barrier width and donor–acceptor distance distribution that controls tunneling probability. Reviews linking hydrogen tunneling to protein dynamics make precisely this point: a successful treatment of H‑tunneling requires multidimensional models that include environmental/protein motions, rather than a purely static barrier picture. The constraint is equally important:even if tunneling enhances a specific enzyme step, fermentation yield is a systems property, and local kinetic gains will translate into yield only when pathway control structure and cellular constraints permit that gain to propagate to net production. #Bioprocess #ScaleUp and #TechTransfer,#Industrial #Microbiology,#MetabolicEngineering and #SystemsBiology,#Bioprocessing,#MicrobialFermentation,#Bio-manufacturing,#Industrial #Biotechnology,#Fermentation Engineering,#ProcessDevelopment,#Microbiology,#Biochemistry,#Biochemical Engineering, #Applied #MicrobialPhysiology, #Microbial #ProcessEngineering, #Upstream #BioprocessDevelopment, #Downstream Processing and #Purification,#CellCulture and #MicrobialSystems Engineering, #Bioreaction #Enzymes, #Biocatalyst #scientific #Scientist #Research

    15 min
  6. Addressing the Biotech Valley of Death as a Systemic Market Failure

    -5 J

    Addressing the Biotech Valley of Death as a Systemic Market Failure

    The episode argues that the biotech "valley of death" is a systemic market failure rather than a simple lack of startup funding. It suggests that moving from laboratory success to industrial production requires specialized infrastructure that behaves more like a public utility than a typical private asset. Because venture capital is often poorly suited for the high costs and long timelines of bioprocess scale-up, the author advocates for shared pilot facilities and milestone-based public funding. These interventions aim to preserve technical know-how and domestic manufacturing capability, even when individual companies struggle. Ultimately, the discussion promotes shifting policy focus from individual startup survival toward building durable industrial sovereignty through coordinated investment and adaptive governance. #Bioprocess #ScaleUp and #TechTransfer, #Industrial #Microbiology, #MetabolicEngineering and #SystemsBiology, #Bioprocessing, #MicrobialFermentation, #Bio-manufacturing, #Industrial #Biotechnology, #Fermentation Engineering, #ProcessDevelopment, #Microbiology, #Biochemistry #Biochemical Engineering, #Applied #MicrobialPhysiology, #Microbial #ProcessEngineering, #Upstream #BioprocessDevelopment, #Downstream Processing and #Purification, #CellCulture and #MicrobialSystems Engineering, #Bioreaction #Enzymes #Biocatalyst #scientific #Scientist #Research

    19 min
  7. Microbial Cell–Broth Separation: Industrial Clarification and Recovery Technologies

    -6 J

    Microbial Cell–Broth Separation: Industrial Clarification and Recovery Technologies

    In this episode we focus on primary cell–broth separation acts as the critical interface between upstream fermentation and downstream purification, converting raw microbial cultures into clarified feed streams. Industrial processes typically utilize centrifugation, filtration, or sedimentation, though the choice depends on complex variables like cell morphology, broth viscosity, and the risk of shear-induced damage. While centrifugation excels at high-throughput bulk solids removal, it often requires depth filtration as a secondary step to capture fine debris and protect subsequent chromatography stages. Filtration offers a gentler alternative for sensitive products but faces challenges from membrane fouling and high consumable costs. Ultimately, successful bioprocessing prioritizes operational robustness over theoretical ideals, frequently employing hybrid systems to manage the inherent variability of microbial life at manufacturing scales. #Bioprocess #ScaleUp and #TechTransfer, #Industrial #Microbiology, #MetabolicEngineering and #SystemsBiology, #Bioprocessing, #MicrobialFermentation, #Bio-manufacturing, #Industrial #Biotechnology, #Fermentation Engineering, #ProcessDevelopment, #Microbiology, #Biochemistry #Biochemical Engineering, #Applied #MicrobialPhysiology, #Microbial #ProcessEngineering, #Upstream #BioprocessDevelopment, #Downstream Processing and #Purification, #CellCulture and #MicrobialSystems Engineering, #Bioreaction #Enzymes #Biocatalyst #scientific #Scientist #Research

    24 min
  8. Harvest Timing as a Risk-Control Lever in Biomanufacturing

    1 FÉVR.

    Harvest Timing as a Risk-Control Lever in Biomanufacturing

    This episode examines how harvest timing serves as a vital tool for managing technical risks in industrial microbial fermentation. Rather than chasing the highest possible product concentration, manufacturers must balance marginal yield gains against the dangers of product degradation and increased impurity levels. My analysis highlights that a multi-layered decision architecture that uses real-time monitoring, such as gas analysis and sensors, to detect metabolic shifts before they compromise the batch. By identifying the specific point where operational risks outweigh production benefits, companies can ensure better consistency and protect downstream processing efficiency. Ultimately, the material advocates for a risk-first approach that prioritizes long-term manufacturing stability over laboratory-scale peak performance. #Bioprocess #ScaleUp and #TechTransfer, #Industrial #Microbiology, #MetabolicEngineering and #SystemsBiology, #Bioprocessing, #MicrobialFermentation, #Bio-manufacturing, #Industrial #Biotechnology, #Fermentation Engineering, #ProcessDevelopment, #Microbiology, #Biochemistry #Biochemical Engineering, #Applied #MicrobialPhysiology, #Microbial #ProcessEngineering, #Upstream #BioprocessDevelopment, #Downstream Processing and #Purification, #CellCulture and #MicrobialSystems Engineering, #Bioreaction #Enzymes #Biocatalyst #scientific #Scientist #Research

    17 min
Tout afficher (45)

À propos

Welcome to Biomanufacturing & Fermentation Technology, the podcast where microbes meet manufacturing and science turns into scalable reality. In each episode, we dive inside real bioprocesses. from lab-scale experiments to commercial fermenters. to unpack how products are actually made, fixed, and optimized in the real world. Expect candid conversations on fermentation failures and breakthroughs, scale-up war stories, regulatory realities, emerging technologies, and the decisions that separate a promising culture from a profitable process. Whether you are a scientist, engineer, entrepreneur, o

Informations